Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results

Niraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistant prostate cancer who were positive for homologous...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Kim N, Fleshner, Neil, Chiuri, Vincenzo Emanuele, Van Bruwaene, Siska, Hafron, Jason, McNeel, Douglas G, De Porre, Peter, Maul, Raymond Scott, Daksh, Mahesh, Zhong, Xiaogang, Mason, Gary E, Tutrone, Ronald F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166146/
https://www.ncbi.nlm.nih.gov/pubmed/36994854
http://dx.doi.org/10.1093/oncolo/oyad008
_version_ 1785038384562962432
author Chi, Kim N
Fleshner, Neil
Chiuri, Vincenzo Emanuele
Van Bruwaene, Siska
Hafron, Jason
McNeel, Douglas G
De Porre, Peter
Maul, Raymond Scott
Daksh, Mahesh
Zhong, Xiaogang
Mason, Gary E
Tutrone, Ronald F
author_facet Chi, Kim N
Fleshner, Neil
Chiuri, Vincenzo Emanuele
Van Bruwaene, Siska
Hafron, Jason
McNeel, Douglas G
De Porre, Peter
Maul, Raymond Scott
Daksh, Mahesh
Zhong, Xiaogang
Mason, Gary E
Tutrone, Ronald F
author_sort Chi, Kim N
collection PubMed
description Niraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistant prostate cancer who were positive for homologous recombination repair gene alterations and had progressed on 1 prior line of novel androgen receptor-targeted therapy. Results from the combination of NIRA with abiraterone acetate plus prednisone, which disrupts androgen axis signaling through inhibition of CYP17, showed promising efficacy and a manageable safety profile in this patient population.
format Online
Article
Text
id pubmed-10166146
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-101661462023-05-09 Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results Chi, Kim N Fleshner, Neil Chiuri, Vincenzo Emanuele Van Bruwaene, Siska Hafron, Jason McNeel, Douglas G De Porre, Peter Maul, Raymond Scott Daksh, Mahesh Zhong, Xiaogang Mason, Gary E Tutrone, Ronald F Oncologist Brief Communication Niraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistant prostate cancer who were positive for homologous recombination repair gene alterations and had progressed on 1 prior line of novel androgen receptor-targeted therapy. Results from the combination of NIRA with abiraterone acetate plus prednisone, which disrupts androgen axis signaling through inhibition of CYP17, showed promising efficacy and a manageable safety profile in this patient population. Oxford University Press 2023-03-30 /pmc/articles/PMC10166146/ /pubmed/36994854 http://dx.doi.org/10.1093/oncolo/oyad008 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Communication
Chi, Kim N
Fleshner, Neil
Chiuri, Vincenzo Emanuele
Van Bruwaene, Siska
Hafron, Jason
McNeel, Douglas G
De Porre, Peter
Maul, Raymond Scott
Daksh, Mahesh
Zhong, Xiaogang
Mason, Gary E
Tutrone, Ronald F
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
title Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
title_full Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
title_fullStr Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
title_full_unstemmed Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
title_short Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
title_sort niraparib with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer: phase ii quest study results
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166146/
https://www.ncbi.nlm.nih.gov/pubmed/36994854
http://dx.doi.org/10.1093/oncolo/oyad008
work_keys_str_mv AT chikimn niraparibwithabirateroneacetateandprednisoneformetastaticcastrationresistantprostatecancerphaseiiqueststudyresults
AT fleshnerneil niraparibwithabirateroneacetateandprednisoneformetastaticcastrationresistantprostatecancerphaseiiqueststudyresults
AT chiurivincenzoemanuele niraparibwithabirateroneacetateandprednisoneformetastaticcastrationresistantprostatecancerphaseiiqueststudyresults
AT vanbruwaenesiska niraparibwithabirateroneacetateandprednisoneformetastaticcastrationresistantprostatecancerphaseiiqueststudyresults
AT hafronjason niraparibwithabirateroneacetateandprednisoneformetastaticcastrationresistantprostatecancerphaseiiqueststudyresults
AT mcneeldouglasg niraparibwithabirateroneacetateandprednisoneformetastaticcastrationresistantprostatecancerphaseiiqueststudyresults
AT deporrepeter niraparibwithabirateroneacetateandprednisoneformetastaticcastrationresistantprostatecancerphaseiiqueststudyresults
AT maulraymondscott niraparibwithabirateroneacetateandprednisoneformetastaticcastrationresistantprostatecancerphaseiiqueststudyresults
AT dakshmahesh niraparibwithabirateroneacetateandprednisoneformetastaticcastrationresistantprostatecancerphaseiiqueststudyresults
AT zhongxiaogang niraparibwithabirateroneacetateandprednisoneformetastaticcastrationresistantprostatecancerphaseiiqueststudyresults
AT masongarye niraparibwithabirateroneacetateandprednisoneformetastaticcastrationresistantprostatecancerphaseiiqueststudyresults
AT tutroneronaldf niraparibwithabirateroneacetateandprednisoneformetastaticcastrationresistantprostatecancerphaseiiqueststudyresults

Ejemplares similares